MaxCyte (NASDAQ:MXCT – Get Free Report) was upgraded by investment analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a note issued to investors on Saturday, Wall Street Zen reports.
MXCT has been the subject of several other research reports. BTIG Research reissued a “neutral” rating on shares of MaxCyte in a research note on Monday, August 24th. Weiss Ratings cut shares of MaxCyte from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, November 4th. Finally, Stifel Nicolaus set a $4.00 price target on shares of MaxCyte in a research note on Thursday, November 12th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $4.50.
Read Our Latest Stock Analysis on MaxCyte
MaxCyte Price Performance
MaxCyte (NASDAQ:MXCT – Get Free Report) last announced its quarterly earnings data on Tuesday, November 10th. The company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.03. The business had revenue of $8.16 million during the quarter, compared to the consensus estimate of $7.39 million. MaxCyte had a negative return on equity of 15.05% and a negative net margin of 81.40%. On average, sell-side analysts anticipate that MaxCyte will post -0.24 earnings per share for the current fiscal year.
Insider Activity
In related news, CEO Maher Masoud purchased 100,000 shares of the stock in a transaction dated Tuesday, November 17th. The stock was bought at an average cost of $1.21 per share, for a total transaction of $121,000.00. Following the completion of the acquisition, the chief executive officer owned 575,000 shares of the company’s stock, valued at approximately $695,750. This represents a 21.05% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 4.10% of the company’s stock.
Institutional Trading of MaxCyte
Hedge funds have recently made changes to their positions in the company. Vitruvian Partners LLP acquired a new position in shares of MaxCyte in the second quarter valued at approximately $6,203,328. Liontrust Investment Partners LLP bought a new position in MaxCyte in the 3rd quarter valued at approximately $5,421,000. BlackRock Inc. acquired a new stake in MaxCyte during the 2nd quarter worth approximately $3,765,000. Renaissance Technologies LLC boosted its position in MaxCyte by 153.3% during the 1st quarter. Renaissance Technologies LLC now owns 1,993,200 shares of the company’s stock worth $1,400,000 after buying an additional 1,206,300 shares during the period. Finally, Stonepine Capital Management LLC acquired a new stake in MaxCyte during the 2nd quarter worth approximately $924,475. 68.81% of the stock is owned by institutional investors and hedge funds.
MaxCyte Company Profile
MaxCyte, Inc. develops and commercializes cell-engineering technology used by biotechnology and pharmaceutical companies, academic research institutions, and cell therapy developers. Its platform is designed to introduce molecules such as DNA, RNA, and proteins into cells while maintaining cell viability, supporting applications in cell therapy, gene editing, and drug discovery. The company’s offerings include its Flow Electroporation systems, related consumables, and services. MaxCyte also works with cell therapy developers through licensing agreements that allow them to use its technology in developing and manufacturing therapeutic products.
Read More
- Five stocks we like better than MaxCyte
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for MaxCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MaxCyte and related companies with MarketBeat.com's FREE daily email newsletter.
